0001493152-21-003198.txt : 20210210 0001493152-21-003198.hdr.sgml : 20210210 20210210060159 ACCESSION NUMBER: 0001493152-21-003198 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210204 FILED AS OF DATE: 20210210 DATE AS OF CHANGE: 20210210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Benathen Marc David CENTRAL INDEX KEY: 0001845258 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39785 FILM NUMBER: 21609100 MAIL ADDRESS: STREET 1: 222 EAST 34TH STREET STREET 2: APT 1214 CITY: NEW YORK STATE: NY ZIP: 10016 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CONVERSION LABS, INC. CENTRAL INDEX KEY: 0000948320 STANDARD INDUSTRIAL CLASSIFICATION: SOAP, DETERGENT, CLEANING PREPARATIONS, PERFUMES, COSMETICS [2840] IRS NUMBER: 760238453 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 800 THIRD AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (866) 351-5907 MAIL ADDRESS: STREET 1: 800 THIRD AVENUE, SUITE 2800 CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: Immudyne, Inc. DATE OF NAME CHANGE: 20120514 FORMER COMPANY: FORMER CONFORMED NAME: IMMUDYNE INC DATE OF NAME CHANGE: 19950720 3 1 ownership.xml X0206 3 2021-02-04 0 0000948320 CONVERSION LABS, INC. CVLB 0001845258 Benathen Marc David C/O CONVERSION LABS, INC, 800 THIRD AVENUE, SUITE 2800 NEW YORK NY 10022 0 1 0 0 Chief Financial Officer Restricted Stock Units 15000 D Options to purchase shares of Common Stock Common Stock, par value $0.001 200000 D Pursuant to the terms of the employment agreement, by and between Mr. Benathen and the Issuer, on February 4, 2021 (the "Effective Date"), Mr. Benathen was granted: (i) 15,000 restricted stock units of the Company's common stock (the "RSUs"), with 3,750 of the RSUs vesting on the Effective Date, and the remaining RSUs scheduled to vest in three equal installments of 3,750, on each of February 4, 2022, February 4, 2023 and February 4, 2024; and (ii) stock options to purchase up to 200,000 shares of the Company's common stock at an exercise price of $21.02 per share (the "Stock Options"). The Stock Options shall vest in equal monthly tranches, based on the passage of time, over the 36 months, beginning on the Effective Date. /s/ Marc Benathen 2021-02-10